Long-term follow-up in lupus nephritis patients treated with rituximab clinical and histopathological response
|
|
- Walter Mitchell
- 6 years ago
- Views:
Transcription
1 RHEUMATOLOGY Rheumatology 2013;52: doi: /rheumatology/kes348 Advance Access publication 3 January 2013 Original article Long-term follow-up in lupus nephritis patients treated with rituximab clinical and histopathological response Thórunn Jónsdóttir 1, Agneta Zickert 1, Birgitta Sundelin 2, Elisabet W. Henriksson 3, Ronald F. van Vollenhoven 4 and Iva Gunnarsson 1 Abstract Objective. To investigate the long-term clinical, histological and serological affects of B-cell-depleting therapy (BCDT) in patients with LN refractory to conventional treatment. Methods. Twenty-five patients, followed for a mean time of 36 (9 95 ), were included. Renal disease activity was evaluated with the BILAG index and renal response was determined according to the LN European consensus statement. Renal biopsies were performed for histological evaluation at baseline and follow-up. Results. Partial response (PR) or complete renal response (CR) was observed in 22 of 25 after a median of 12. Sixteen patients achieved CR after a median of 24. Six patients experienced a renal relapse. Proteinuria decreased significantly (P = ) from baseline to 36. A noteworthy histological improvement was seen in nearly all patients with a significant reduction in activity index (P = 0.01). Longer depletion time and low baseline values of IgM were indicative of achieving clinical remission during the first year after treatment (P = 0.03 and P = 0.04, respectively). Conclusion. In therapy-resistant LN, BCDT induced clinical and histological improvements in the majority of patients. Transition from PR to CR was mainly seen during the second year of follow-up. Patients with longer depletion time and low baseline levels of IgM were more likely to gain a faster remission, suggesting that the clinical benefit may be linked to suppression of autoreactive plasmablasts. Although formal evidence of BCDT in LN is lacking, our data may provide guidance to clinicians considering therapeutic options in patients with refractory LN. Key words: systemic lupus erythematosus, lupus nephritis, rituximab, anti-cd20, B-cell depletion. CLINICAL SCIENCE Introduction Nephritis remains a major cause of morbidity in patients with SLE and repeated renal flares are known to be a risk factor for development of end-stage renal disease [1]. Despite common knowledge and application of intensive treatment regimens involving CSs and CYC [2 6], and in 1 Department of Medicine, Rheumatology Unit, 2 Department of Oncology and Pathology, Pathology and Cytology, 3 Department of Neurobiology, Care Sciences and Society and 4 Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden. Submitted 22 March 2012; revised version accepted 18 October Correspondence to: Thórunn Jónsdóttir, Department of Medicine, Rheumatology Unit, Landspitali University Hospital, 108, Reykjavík, Iceland. torunnjo@landspitali.is later years MMF [7 9], there is still significant morbidity and mortality associated with LN [10]. A significant proportion of patients still have refractory disease or are unable to tolerate conventional immunosuppressive agents [11]. Increased understanding of the immunopathogenesis of SLE and LN as well as the lack of treatment options in severe LN has resulted in the development of new immunomodulatory therapies. In later years, B-cell depletion with rituximab (RTX) has shown promising results in several open uncontrolled studies in patients with refractory LN [12 21]. However, controlled clinical trials with RTX in LN have so far been unsuccessful [22]. We have previously reported on the clinical and histopathological course of patients with LN treated with RTX in a short-term follow-up study [16]. Here we present! The Author Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please journals.permissions@oup.com
2 Thórunn Jónsdóttir et al. longer-term clinical results and data regarding predictors of response to B-cell depletion with RTX in an expanded cohort of patients with LN refractory to conventional therapy. Patients and methods Patients and study design Twenty-five patients with active SLE and LN proven by a recent renal biopsy were treated with RTX in combination with i.v. CYC and glucocorticoids (GCs). All but two patients were earlier refractory to conventional therapy including CYC and/or MMF. The patients were followed according to a standardized protocol until a renal flare occurred or re-treatment with RTX was given for non-renal lupus manifestation. Minimum time of follow-up was 2 years. All patients fulfilled at least four of the ACR criteria for SLE [23]. Eighteen of the patients have previously been reported [24]. The study was approved by the local ethics committee (Karolinska Institutets Etikråd) and the Swedish Medical Product Agency. All patients were informed and consented to the treatment. The patient demographics are presented in Table 1. Treatment protocol The protocol has previously been reported in detail [16]. Briefly, i.v. RTX 375 mg/m 2 was given once weekly for 4 weeks. CYC 0.5 g i.v. was given in combination with the first and fourth RTX infusion. An exception was made in four patients, two of whom were treated with RTX in combination with MMF and two with RTX as monotherapy. Five patients were treated with two infusions of RTX at 1000 mg each, 2 weeks apart. One patient received only three doses of RTX and one dose of CYC due to an infusion reaction at the start of the third infusion. GCs were temporarily increased during the treatment weeks (0.5 mg/kg) but tapered rapidly thereafter. After RTX, and during the time of B-cell depletion, concomitant immunosuppression was stopped according to the treatment protocol used and no other immunosuppressive therapy than anti-malarials was allowed (except in one patient in whom prior MMF treatment was continued). All patients with the exception of three (nos 4, 5 and 6) were treated with angiotensin-converting enzyme blocker and/or angiotensin receptor blocker. After the reappearance of B cells in the circulation, 10 of 25 patients were put on maintenance therapy mainly with MMF (n = 8) or AZA (n = 2). Of the remaining 15 patients TABLE 1 Patient demographics at baseline No. Age, years Disease duration, years Previous and ongoing therapy Time of follow-up, Time of B cell return, Maintenance therapy Time to flare, Time to PR/CR, AML, AZA, MMF, MTX, CYC a 40 9 AML 40 b 6/ AZA, CYC, CSA a 95 2 MMF 24/ CYC, CSA a, MMF a MMF 60 6/ CYC, AML a, CSA, MTX 21 6 None 21 b 12/not AZA, CYC a 12 3 None 12 Not AM, MMF, AZA, MTX, CYC a 65 8 AML 6/ MTX, AZA, AML, CSA, CYC a 15 6 None 15 c 12/not CSA, CYC a 64 5 None 64 24/ CYC, AZA a 10 6 None 10 6/ MMF, CYC a 46 4 MMF 6/ None a MMF 24/ CYC, None a 41 2 AZA 6/not 13 d 58 4 CYC, MMF a 39 3 MMF 12/not AZA, MMF, CYC a 41 8 None 12/ CSA, CYC, AZA a, AML a AML 6/ MTX, CYC, MMF a 36 5 None 36/ CYC, AZA, MMF a 17 6 MMF 17 6/not 18 e AZA, CYC, MMF a 9 6 None NR Not AML, AZA, CYC, MMF a None 11 Not AZA, MMF a 12 Still depleted None 6/12 at CYC, AZA a, CSA a 71 ND MMF 24/not 22 d 31 9 CYC, AZA, AML a AZA 12/ AZA, CYC, AML a, MMF a 27 ND AML 6/24 24 e 18 1 AML, MMF a 18 6 MMF 18/not AML, MMF, CYC a 24 7 None 12/24 Patients nos 21 and 25 are male. Patients nos 22 and 24 are African and patients nos 3 and 20 are Asian. All other patients are Caucasian. NR: non-responder; ND: not determined; AML: anti-malarials. a Ongoing therapy. b Retreated for non-renal flare. c Leukeran for non-renal flare. d MMF instead of CYC in combination with RTX. e RTX monotherapy
3 Long-term follow-up in LN 11 were treated with low-dose GC, combined with antimalarials in four cases (Table 1). Follow-up evaluation All patients were followed using a standardized protocol every second to third month during the first year and every 6 thereafter. The global disease activity was evaluated using the SLEDAI [25]. Renal disease activity was assessed by the BILAG index [26]. Blood sampling included investigation of serum creatinine and serum albumin levels, serology and complement. Glomerular filtration rate (GFR) was assessed by urinary clearance of Iohexol according to clinical routine or assessed using the Modification of Diet in Renal Disease (MDRD) formula [27]. Circulating B cells in the peripheral blood were investigated by detection of CD19 + B cells and analysed by flow cytometry at baseline, month 1, month 2 and every other month thereafter. The limit for detection of CD19 + B cells was < /l (normal ). Renal evaluation and histopathology Renal evaluation included urinalysis (dip slide procedure), urine sediment and investigation of 24-h protein excretion. Repeated renal biopsies were performed related to the 6-month follow-up time point. All biopsies were graded according to the World Health Organization (WHO) classification [28] and activity and chronicity indices were recorded [29]. All biopsies were evaluated by light microscopy, IF and electron microscopy, including evaluation of at least two glomeruli. Renal response and relapse For evaluation of the renal response the LN European consensus statement was used [30]. In these statements the ACR response criteria for proliferative and membranous renal disease in SLE clinical trials [31] and the EULAR guidelines for clinical trials [32, 33] were taken into consideration along with opinions from a panel of experts on LN. According to these criteria, evaluation of renal function (GFR), urinary protein level (here assessed by 24-h urinary protein excretion), abnormalities in urinary sediment and adverse events were recorded in order to evaluate renal response, complete response (CR) and partial response (PR), no response and flares. According to these consensus statements a renal flare was defined as increased disease activity requiring more intensive therapy and indicated by an increase in proteinuria or serum creatinine, abnormal urinary sediment or a reduction in creatinine clearance due to active disease. We also regarded any new renal BILAG A or B as a renal flare. Serology and complement levels Analysis of serum IgG anti-dsdna antibodies was performed by a fluorescent enzyme immunoassay method (Pharmacia, Uppsala, Sweden). The cut-off for normal was <15 IU/ml but values below this level were recorded for statistical calculations. C3 and C4 were determined by nephelometry (normal range g/l for C3 and g/l for C4). Analysis of complement component C1q was performed by rocket electrophoresis [34] using rabbit anti-c1q as the antibody. Levels of C1q were expressed as the percentage of the levels of normal blood donors (normal %). Total serum Igs G, A and M were measured by ELISA (normal range g/l for IgG, g/l for IgA and g/l for IgM). Statistics For comparison of variables at baseline and follow-up, Student s t-test was used for normally distributed parameters and the non-parametric Mann Whitney test for non-normally distributed parameters. Correlations were calculated and significance determined by Fisher s r-to-z test. Kaplan Meier hazard plots were constructed for time to PR/CR and time to flare. For these analyses, Statview (SAS Institute, Cary, NC, USA) was used. P < 0.05 was considered significant. Results All but 2 of the 25 patients were female and all but 4 were of Caucasian origin (2 were Asian, 2 African). The mean age at treatment was 35 years (range years) and the mean time from SLE diagnosis was 8 years (range 1 22 years) (Table 1). At inclusion the mean SLEDAI score was 16 (range 6 36) and all patients had a renal BILAG A; the mean prednisolone dose was 17 mg/day (range 0 40 mg/day). At 6 of follow-up, the mean dose had decreased to 10 mg/day (range mg/day) (P = 0.02). The patients were followed for a mean of 36 (range 9 95 ). Eighteen of the patients reached 2 years and 14 patients reached 3 years of follow-up. Follow-up evaluation The mean creatinine at study start was 100 nmol/l (range nmol/l) and was reduced to a mean of 84 nmol/l (range nmol/l) at 6 (P = not significant). Serum albumin increased from a mean of 27 g/l (range g/l) to 33 g/l (range g/l) at 6 (P < ). The most prominent reduction of proteinuria was seen during the first 6, with a reduction from a mean of 3 g/24 h to 1.1 g/24 h (P = ). After 1 year an additional reduction was noted from a mean of 1.1 g/24 h at 12 to 0.5 g/24 h at 24 in the 17 patients available for follow-up. At 36 an additional improvement was noticed with a mean proteinuria of 0.1 g/ 24 h (P < 0.05) in 14 patients available for follow-up (Fig. 1). The mean estimated GFR remained stable during follow-up. All patients had complete peripheral blood B-cell depletion. The CD19 + B cells were detectable in the circulation after a mean time of 8 (range 2 26 ). Add-on of maintenance treatment was decided by the treating physician (Table 1). No relationship was found between the maintenance therapy and response or time to flare (data not shown)
4 Thórunn Jónsdóttir et al. FIG. 1Reduction in proteinuria Proteinuria, g/24h Histological assessment At baseline, 15 of the 25 patients had proliferative LN (WHO III or IV), 9 of 25 had membranous LN (WHO V) and 1 patient refused renal biopsy (Table 1). Nineteen patients underwent a re-biopsy after a mean time of 8 (range 3 12 ). Histological improvements with transformation in WHO class at re-biopsy was seen in a majority of the patients with proliferative nephritis. In all patients there was a significant reduction in activity index from 4.5 to 2.3 (P = 0.001) and an unchanged chronicity index (data not shown). For detailed information regarding biopsy findings, see Table 2. Renal responses P= P= P<0.05 P< Months Twenty-four-hour albumin excretion decreased from a mean of 3.0 g/day (range g/day) to 1.1 g/day (range g/day) at both 6 and 12 and was further reduced to 0.5 g/day (range g/day) at 24 (P < 0.05) and to 0.1 g/day (range g/day) at 36 (P < 0.05). A significant reduction was seen between 6 and 36 (P < 0.05) and between 12 and 36 (P < 0.05), respectively. A reduction was also seen between 12 and 24, although it was not significant (P = 0.057). When comparing the two different sets of response criteria we found full agreement between the PR/CR consensus criteria [30] and achieving BILAG C/D. As the two renal response criteria used here were fully comparable, we choose to clarify BILAG C as PR and BILAG D as CR. One patient was a non-responder with persistent BILAG A. Two patients were considered poor responders, with a BILAG B at best (Fig. 2). The 22 remaining patients achieved a PR at some time point during follow-up, after a median time of 12 (range 6 36 ). Sixteen patients achieved a CR after a median of 24 (range 6 36 ). The likelihood of achieving PR during the first year was >50%, while the majority attaining a CR achieved this during the period from 12 to 24. Figure 3A and B illustrates the time course for achieving PR and CR. Renal relapse Six renal flares occurred after a mean time of 29 (range ). Both patients considered poor responders had a worsening of disease within the first year after treatment (Fig. 2). Four patients reaching a PR or CR flared, one within the first year, one after 17 and the remaining two patients after 60 and 64, respectively (Fig. 2). The four early flares all had proliferative disease (WHO III/IV) on pre-treatment kidney biopsy, while the two late flares had membranous LN (WHO V). None of the patients experiencing a flare within the first year of follow-up had been treated with maintenance immunosuppressive therapy, while the patient flaring after 17 had been taking MMF for 6. One of the patients experiencing a late flare was treated with MMF as maintenance therapy, while the other was under treatment with low doses of oral GC only (5 7.5 mg daily). Eight of 15 patients without maintenance therapy continued to do well 1 year after RTX treatment (Table 1). Serology and complement levels Anti-dsDNA antibodies were detectable in all but one patient at study start, with a mean titre of 202 IU/ml (range IU/ml). At 6 the mean titre had decreased to 107 IU/ml (range IU/ml) (P = ). Complement levels C3, C4 and C1q increased from baseline to 6 of follow-up (P < 0.01) and were kept stable thereafter (data not shown). Total IgG and IgA levels were stable throughout the observation period. A significant reduction was seen in total IgM levels at 6 and 12 compared with baseline (P < 0.01), although values remained within the normal range (data not shown). Predictors of response In patients who achieved a CR within the first 12 a significantly longer time to repopulation of B cells in the circulation was noted (P = 0.03) (Fig. 4A) compared with patients who did not achieve this goal. Furthermore, in patients who achieved a CR, baseline titres of IgM were positively correlated to the time to response (r = 0.53, P = 0.04, 95% CI 0.14, 0.84) (Fig 4B). A trend between low baseline peripheral blood B cells (CD19 + cells) and early achievement of a PR (r = 0.5, P = 0.06) was noted, however, it did not reach statistical significance. There were no correlations regarding complement level or serological status in association with outcome or flares. No correlation was found between response and histopathological classification. Adverse events Adverse events noted during the first 6 of followup included urinary tract infections (n = 3), Salmonella infection (n = 1), reactivation of herpes zoster (n = 2), infusion reaction (n = 3, two mild and one moderate). Severe adverse events were noted in four patients. One neutropenic fever was diagnosed 1 week after the last CYC and RTX 850
5 Long-term follow-up in LN TABLE 2 Histological information on kidney biopsies at baseline and at re-biopsy No. WHO classification at baseline WHO classification at re-biopsy AI/CI at baseline AI/CI at re-biopsy Time from treatment to re-biopsy, 1 IIIb Ib 5/8 1/8 3 2 IVc Vb 5/7 3/7 5 3 Vb ND 4/6 ND 12 4 ND ND ND ND ND 5 IVb IVd 5/1 2/ IVc IIIb 7/3 4/ IIIb IIb 13/3 2/2 7 8 Vb Vb 2/0 2/0 7 9 IVb IIb 7/4 4/ IVb IIb 10/1 2/ Vb Va 2/1 3/ Vb IIa 2/6 1/ Vb Vb/IIb 3/5 2/ Vb/IIIb Vb 9/3 1/ IIIb Va ND 1/ IIIb Vasculitis 5/3 5/ IV/Vb IVa 3/0 1/ IV IVa/V 3/2 4/ IV c IIB/V 5/3 2/ Va VA 1/0 1/ IV IV ND ND 9 22 IV a ND 1/2 ND ND 23 III ND ND ND ND 24 V ND ND ND ND 25 IVa IB 3/4 1/6 10 ND: not determined; AI: activity index; CI: chronicity index. FIG. 2Flow chart with overview of patient s response to therapy. Total 25 patients with LN Clinical response PR or CR 22 patients Non- / poor responders 3 patients CR 16 patients PR 6 patients Flare Flare Flare Non-responder 3 patients 1 early (10 ) 2 late (60 vs 64 ) 1 patient (17 ) 2 patients (11/12 ) 1 patient 851
6 Thórunn Jónsdóttir et al. FIG. 3Kaplan Meier curves showing time to BILAG C (PR) and D (CR). Share achieving BILAG C Share achieving BILAG D infusions. Additionally two patients were diagnosed with severe neutropenia, one in close correlation with the first CYC infusion while the other was diagnosed 3 after the treatment period. Severe necrotizing fasciitis and septicaemia was diagnosed in one patient 5 after treatment. Discussion Time, Time, (A) Time to achieve a renal BILAG C (PR). After 6 40% of patients have reached a BILAG C (PR) and after 12 60%. (B) Time to achieve a renal BILAG D (CR). After 6 12% had reached a BILAG D (CR) and after 12 20%. After 24 50% of patients had achieved a renal BILAG D (CR). In long-term follow-up, treatment with the combination of RTX and CYC in patients with therapy-resistant LN was here shown to induce a beneficial renal response in the majority of patients. The findings thus confirm our previous results on short-term clinical and histological efficacy of RTX in severe proliferative LN [16], also shown by others [35 37]. In the current report, renal response mainly occurred during the first year following treatment, but many of the patients further achieved a CR after 2 years of follow-up. In parallel, repeat renal biopsies in the early phase showed a significant improvement, which confirms the clinical response seen. A faster response A B was seen in patients with lower baseline levels of IgM and longer depletion time was positively correlated with time to response. A trend towards an association between low absolute numbers of CD19 + cells at baseline and more rapid responses was noted. In the context of the present study it should be noted that the Lupus Nephritis Assessment with Rituximab (LUNAR) clinical trial, investigating the efficacy of RTX in patients with LN in a double-blind, randomized trial, failed to achieve its primary endpoint, although the serological improvement was statistically better in the RTX group [22]. However, our study differs significantly from the LUNAR trial in being an open observational study reflecting reallife clinical LN patients. Importantly in contrast to the patients in LUNAR, the population treated here had failed conventional treatment, thus having an increased likelihood to be poor responders. Despite this we were able to demonstrate a clinical as well as histopathological improvement, shown here by a significant decrease in renal activity indices and reduction of proteinuria. The time for development of PR varied to some extent, although the majority of patients achieved this within 12. In contrast, the time to CR was longer, in most cases being documented between 12 and 24 of follow-up. These data suggest that comparative trials of RTX, or other B-cell depleting agents, may have to be designed to include longer follow-up periods in order to increase the likelihood of capturing complete responders in the differentiation between active treatment and comparators. We reported earlier on the correlation of low baseline CD19 + cells and beneficial clinical outcome after treatment with RTX in lupus patients [38]. In the present report, this correlation did not reach statistical significance, although a trend was noted between low numbers of CD19 + cells at baseline and a better renal outcome. Interestingly, a delay in repopulation was found to increase the likelihood for achieving a CR within the first year. Furthermore, patients with lower values of IgM at baseline were found more likely to achieve a CR. It could be speculated that high baseline number of CD19 + cells and titres of IgM could reflect the presence of a greater number of autoreactive plasma cells in the lymphoid and/or target tissues. In accordance with these findings, it is believed that in patients with RA the disappearance of these cells is needed for a better clinical response [39, 40]. It has also been indicated that suboptimal depletion of B cells and B-cell-derived plasma cells in the tissue of RA patients may be associated with a poorer clinical response [41]. Many studies have reported on the beneficial effects of maintenance agents in LN regardless of the type of induction treatment [42]. It could thus be debated whether, or when, additional immunosuppressive therapy should be initiated routinely after RTX therapy in the prevention of renal flares. However, this study was not designed to address this issue. Despite inclusion of patients with previous poor response to immunosuppressives, the flare rate observed 852
7 Long-term follow-up in LN FIG. 4Time to BILAG D in association with depletion time and baseline IgM. A Months to return of CD19 + cells B Time to BILAG D, n =18 n No BILAG D within first 12 Mean 6 P= Baseline IgM, g/l was comparatively low, also taking into account that the patients included had relapsing disease at inclusion, thus being selected for having a more severe disease course. However, the low number and the variable time points make it difficult to draw any conclusions on factors predicting the development of renal flares in the current patient material. In a collaborative study we previously showed similar serological and urine outcomes comparing proliferative and membranous LN patients treated with RTX. In line with these findings, we found no difference in response rate regarding histopathological classification, although this has recently been described by others [20]. The main limitations of our study are its open observational nature, that it is non-blinded and that it has a limited number of subjects. It is strengthened by the facts that it presents real-life refractory patients and is supported by histological data before and after treatment. y n =4 Achieving BILAG D within first 12 Mean 10 r =0.53, P=0.04 (A) Patients achieving a renal BILAG D (CR) within the first 12 had a longer time to return of B cells in the circulation compared with those not achieving this goal (r = 0.53; 95% CI 0.25, 0.82; P = 0.03). (B) Patients with lower baseline values of IgM showed a significantly shorter time to achieve a renal BILAG D (CR) (r = 0.53; 95% CI 0.14, 0.84; P = 0.01). While formal evidence of the efficacy of RTX in LN is still lacking, our data may provide guidance to clinicians considering therapeutic options with RTX as induction treatment in patients with refractory SLE and renal disease. Rheumatology key messages. B-cell-depleting therapy with RTX and CYC may give long-term clinical and histological improvement in refractory LN.. In LN treated with RTX + CYC transition from PR to CR was mainly seen during the second year of follow-up.. Longer follow-up may be required to evaluate renal response in LN trials. Funding: This work was supported by a grant from King Gustaf V s 80th Birthday Fund and by funds from the Karolinska Institute, the Swedish Research Council and a fund for renal research and the Swedish Rheumatism Association. Disclosure statement: R.F.vV. has received consultancy fees and honoraria from Abbott, GSK, MSD, Pfizer, Roche and UCB Pharma, and grants and research support from Abbott, GSK, MSD, Pfizer, Roche and UCB Pharma. All other authors have declared no conflicts of interest. References 1 Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003;82: Austin HA 3rd, Klippel JH, Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314: Boumpas DT, Austin HA 3rd, Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340: Gourley MF, Austin HA 3rd, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125: Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135: Houssiau FA, Vasconcelos C, D Cruz D et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010;69: Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
8 Thórunn Jónsdóttir et al. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343: Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16: Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353: Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology 2011;50: Houssiau FA, Ginzler EM. Current treatment of lupus nephritis. Lupus 2008;17: Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 2005;44: Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005;52: van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-cd20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 2004;33: Jacobson SH, van Vollenhoven R, Gunnarsson I. Rituximab-induced long-term remission of membranous lupus nephritis. Nephrol Dial Transplant 2006;21: Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007;56: Vigna-Perez M, Hernandez-Castro B, Paredes- Saharopulos O et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006;8:R Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006;54: Lindholm C, Borjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M. Longterm clinical and immunological effects of anti-cd20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008;35: Diaz-Lagares C, Croca S, Sangle S et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012;11: Cervera R, Abarca-Costalago M, Abramovicz D et al. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the Euro-Lupus Project. Autoimmun Rev 2006;5: Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64: Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25: Jonsdottir T, Gunnarsson I, Mourao AF, Lu TY, van Vollenhoven RF, Isenberg D. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology 2010;49: Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35: Hay EM, Bacon PA, Gordon C et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: Leung YY, Lo KM, Tam LS, Szeto CC, Li EK, Kun EW. Estimation of glomerular filtration rate in patients with systemic lupus erythematosus. Lupus 2006;15: Churg J SL. Renal disease. Classification and atlas of glomerular disease. Tokyo: Igaku-Shoin, Austin HA 3rd, Muenz LR, Joyce KM et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983;75: Gordon C, Jayne D, Pusey C et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 2009;18: The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006;54: Bertsias G, Ioannidis JP, Boletis J et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67: Bertsias G, Gordon C, Boumpas DT. Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus 2008;17: Laurell AB, Johnson U, Martensson U, Sjoholm AG. Formation of complexes composed of C1r, C1s, and C1 inactivator in human serum on activation of C1. Acta Pathol Microbiol Scand 1978;86C: Boletis JN, Marinaki S, Skalioti C, Lionaki SS, Iniotaki A, Sfikakis PP. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant 2009;24: Pepper R, Griffith M, Kirwan C et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009;24:
9 Long-term follow-up in LN 37 Catapano F, Chaudhry AN, Jones RB, Smith KG, Jayne DW. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant 2010;25: Jonsdottir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008;67: Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001;40: Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 1999;97: Thurlings RM, Vos K, Gerlag DM, Tak PP. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum 2008;58: Contreras G, Tozman E, Nahar N, Metz D. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 2005;14(Suppl 1):S
LONG-TERM OUTCOME OF PATIENTS WITH LUPUS NEPHRITIS: A SINGLE CENTER EXPERIENCE
& LONG-TERM OUTCOME OF PATIENTS WITH LUPUS NEPHRITIS: A SINGLE CENTER EXPERIENCE Senija Rašić 1 *, Amira Srna 1, Snežana Unčanin 1, Jasminka Džemidžić 1, Damir Rebić 1, Alma Muslimović 1, Maida Rakanović-Todić
More informationTaming the wolf: Treating to target, treating to remission new strategies for SLE
Taming the wolf: Treating to target, treating to remission new strategies for SLE Ronald van Vollenhoven Seattle, April 28, 2017 Disclosures Research support, consultancy: Abbott (AbbVie), Biotest, BMS,
More informationLupus Related Kidney Diseases. Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017
Lupus Related Kidney Diseases Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017 Financial Disclosures MedImmune Lupus Nephritis Kidney Biopsy Biomarkers
More informationLupus and Your Kidneys. Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia
Lupus and Your Kidneys Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia Kidney Inflammation and Abnormal Function as a Result of Lupus (Lupus
More informationAdditional file 2: Details of cohort studies and randomised trials
Reference Randomised trials Ye et al. 2001 Abstract 274 R=1 WD=0 Design, numbers, treatments, duration Randomised open comparison of: (45 patients) 1.5 g for 3, 1 g for 3, then 0.5 to 0.75 g IV cyclophosphamide
More informationRecent advances in management of Pulmonary Vasculitis. Dr Nita MB
Recent advances in management of Pulmonary Vasculitis Dr Nita MB 23-01-2015 Overview of the seminar Recent classification of Vasculitis What is new in present classification? Trials on remission induction
More informationSevere lupus nephritis: the predictive value of a 50% reduction in proteinuria at 6 months
Nephrol Dial Transplant (2013) 28: 2313 2318 doi: 10.1093/ndt/gft201 Advance Access publication 19 June 2013 Severe lupus nephritis: the predictive value of a 50% reduction in proteinuria at 6 months Stephen
More informationBeyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis
Nephrol Dial Transplant (2013) 28: 106 111 doi: 10.1093/ndt/gfs285 Advance Access publication 3 July 2012 Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis Marc Weidenbusch, Christoph
More informationLupus Nephritis New (?) Treatments. Aurélie HUMMEL Service de Néphrologie Hôpital Necker Enfants-Malades Paris
Lupus Nephritis New (?) Treatments Aurélie HUMMEL Service de Néphrologie Hôpital Necker Enfants-Malades Paris Introduction Lupus nephritis : 30-50% of patients with lupus = mortality risk factor Mok Series
More informationIdentification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome
To cite: Dall Era M, Levesque V, Solomons N, et al. Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Science
More informationIntravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis
Int Urol Nephrol (2013) 45:1301 1308 DOI 10.1007/s11255-012-0331-9 NEPHROLOGY - ORIGINAL PAPER Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis Prayong Vachvanichsanong
More informationSwitching Treatment Between Mycophenolate Mofetil and Azathioprine in Lupus Patients: Indications and Outcomes
Arthritis Care & Research Vol. 66, No. 12, December 2014, pp 1905 1909 DOI 10.1002/acr.22364 2014, American College of Rheumatology ORIGINAL ARTICLE Switching Treatment Between Mycophenolate Mofetil and
More informationLupus nephritis. Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic
Lupus nephritis Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic Disclosure of Interests Abbvie, Amgen, Baxter, Bayer, Boehringer-Ingelheim, Calliditas, Chemocentryx,
More informationREPEATED B CELL DEPLETION IN TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
ARD Online First, published on November 3, 2005 as 10.1136/ard.2005.044487 REPEATED B CELL DEPLETION IN TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS Concise report Kristine P. Ng 1 Maria J. Leandro
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Wed, 20 Jun 2018 01:15:28 GMT) CTRI Number Last Modified On 29/12/2012 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationEfficacy and Safety of Belimumab in the treatment of Systemic Lupus Erythematosus: a Prospective Multicenter Study.
1. Title Efficacy and Safety of Belimumab in the treatment of Systemic Lupus Erythematosus: a Prospective Multicenter Study. 2. Background Systemic Lupus Erythematosus (SLE) is a chronic, autoimmune and
More informationLong-term Outcome of Diffuse Proliferative Lupus Glomerulonephritis Treated with Cyclophosphamide
The American Journal of Medicine (2006) 119, 355.e25-355.e33 CLINICAL RESEARCH STUDY Long-term Outcome of Diffuse Proliferative Lupus Glomerulonephritis Treated with Cyclophosphamide Chi Chiu Mok, MD,
More informationIRACON Management of Lupus Nephritis: Old is gold, New is Trendy
IRACON 2016 Management of Lupus Nephritis: Old is gold, New is Trendy First episode of LN (III/IV): Induction Low dose is equally considerable as high dose CYC Switch to the other agent if no improvement
More informationElevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab
(2016) 25, 346 354 http://lup.sagepub.com PAPER Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab DA Roth 1, A Thompson 2, Y Tang 2*, AE
More informationWillcocks et al.,
ONLINE SUPPLEMENTAL MATERIAL Willcocks et al., http://www.jem.org/cgi/content/full/jem.20072413/dc1 Supplemental materials and methods SLE and AASV cohorts The UK SLE cohort (n = 171) was obtained from
More informationANCA+ VASCULITIDES CYCAZAREM,
ANCA+ VASCULITIDES CYCAZAREM, q Comparison of 3 to 6 mo. oral CYC + CS then azathioprine or oral CYC for 12 mo.+ 10 mg/d CS. After 12 mo all the patients were treated with azathioprine q 150 patients followed
More informationOutcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center study
Sigdel et al. BMC Nephrology (2016) 17:145 DOI 10.1186/s12882-016-0361-0 RESEARCH ARTICLE Open Access Outcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center
More informationN. Hiramatsu, T. Kuroiwa, H. Ikeuchi, A. Maeshima, Y. Kaneko, K. Hiromura, K. Ueki and Y. Nojima
Rheumatology 28;47:72 77 Advance Access publication 4 April 28 doi:1.193/rheumatology/ken19 Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion
More informationEfficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
More informationENFERMEDADES AUTOINMUNES SISTÉMICAS. Dr. José María Pego Reigosa
ENFERMEDADES AUTOINMUNES SISTÉMICAS Dr. José María Pego Reigosa ABSTRACT NUMBER: 2754 Comparison of Individually Tailored vs Systematic Rituximab Regimens to Maintain ANCA-Associated Vasculitis Remissions:
More informationNew Evidence reports on presentations given at EULAR Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis
New Evidence reports on presentations given at EULAR 2011 Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis Report on EULAR 2011 presentations Anti-TNF failure and response to rituximab
More informationGuidance for Industry Lupus Nephritis Caused By Systemic Lupus Erythematosus Developing Medical Products for Treatment
Guidance for Industry Lupus Nephritis Caused By Systemic Lupus Erythematosus Developing Medical Products for Treatment U.S. Department of Health and Human Services Food and Drug Administration Center for
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Idiopathic membranous nephropathy: use of other therapies GUIDELINES
Idiopathic membranous nephropathy: use of other therapies Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES No recommendations possible based on Level I or II evidence
More informationSYSTEMIC LUPUS ERYTHEMATOSUS: CURRENT CONCEPTS AND CLINICAL PEARLS. Dr Sheila Vasoo Consultant Division of Rheumatology NUHS
SYSTEMIC LUPUS ERYTHEMATOSUS: CURRENT CONCEPTS AND CLINICAL PEARLS Dr Sheila Vasoo Consultant Division of Rheumatology NUHS Listen to the Patient Concepts Diagnosis Immunopathogenesis Clinical Pearls Disease
More informationCommittee Approval Date: May 9, 2014 Next Review Date: May 2015
Medication Policy Manual Policy No: dru248 Topic: Benlysta, belimumab Date of Origin: May 13, 2011 Committee Approval Date: May 9, 2014 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationSignificance of Anti-C1q Antibodies in Patients with Systemic Lupus Erythematosus as A Marker of Disease Activity and Lupus Nephritis
THE EGYPTIAN JOURNAL OF IMMUNOLOGY Vol. 23 (1), 2016 Page: 00-00 Significance of Anti-C1q Antibodies in Patients with Systemic Lupus Erythematosus as A Marker of Disease Activity and Lupus Nephritis 1
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jones RB, Cohen Tervaert JW, Hauser T, et al. Rituximab versus
More informationREMISSION OF ACTIVE LUPUS NEPHRITIS WITH VOCLOSPORIN: RESULTS OF THE AURA-LV STUDY
REMISSION OF ACTIVE LUPUS NEPHRITIS WITH VOCLOSPORIN: RESULTS OF THE AURA-LV STUDY V. Dobronravov* 1, M. A. Dooley 2, S. A. Haq 3, I. Adzerikho 4, O. Bugrova 5, D. Isenberg 6, F. Houssiau 7, N. Solomons
More informationANCA associated vasculitis in China
ANCA associated vasculitis in China Min Chen Renal Division, Peking University First Hospital, Beijing 100034, P. R. China 1 General introduction of AAV in China Disease spectrum and ANCA type Clinical
More informationEffect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus.
Thomas Jefferson University Jefferson Digital Commons Department of Medicine Faculty Papers Department of Medicine 10-22-2015 Effect of mycophenolate mofetil on the white blood cell count and the frequency
More informationIn the United States, induction therapy for the treatment of
Oral Cyclophosphamide for Lupus Glomerulonephritis: An Underused Therapeutic Option Alison McKinley,* Edward Park,* Dan Spetie,* Kevin V. Hackshaw, Smitha Nagaraja,* Lee A. Hebert,* and Brad H. Rovin*
More informationClinical Commissioning Policy Statement: Rituximab For Systemic Lupus Erythematosus (SLE) December Reference : NHSCB/A3C/1b
Clinical Commissioning Policy Statement: Rituximab For Systemic Lupus Erythematosus (SLE) December 2012 Reference : NHSCB/A3C/1b NHS Commissioning Board Clinical Commissioning Policy Statement: Rituximab
More informationChapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, ; doi: /kisup.2012.
http://www.kidney-international.org & 2012 KDIGO Chapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, 172 176; doi:10.1038/kisup.2012.17 INTRODUCTION This
More informationResearch Article Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
Autoimmune Diseases, Article ID 731806, 4 pages http://dx.doi.org/10.1155/2014/731806 Research Article Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus Fabio
More informationRonald F. van Vollenhoven Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) The Karolinska Institute Stockholm, Sweden
Ronald F. van Vollenhoven Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) The Karolinska Institute Stockholm, Sweden Disclosures Research Grants: AbbVie, Amgen, BMS, GSK, Pfizer, Roche,
More informationBenlysta (belimumab) Prior Authorization Criteria Program Summary
Benlysta (belimumab) Prior Authorization Criteria Program Summary This prior authorization applies to Commercial, NetResults A series, NetResults F series and Health Insurance Marketplace formularies.
More informationTREATMENT OF ANCA-ASSOCIATED VASCULITIS
TREATMENT OF ANCA-ASSOCIATED VASCULITIS Loïc Guillevin Hôpital Cochin, Université Paris Descartes Cours DU, 11 mars 2016 1 Disclosure of interest regarding this presentation Roche has provided, in part,
More informationMycophenolate Mofetil for Induction Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis
Mycophenolate Mofetil for Induction Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis Michael Walsh,* Matthew James,* David Jayne, Marcello Tonelli, Braden J. Manns,* and Brenda R. Hemmelgarn*
More informationReview B cell targeted therapies Edward Keystone
Available online http://arthritis-research.com/contents/7/s3/s13 Review B cell targeted therapies Edward Keystone Department of Medicine, University of Toronto, Ontario, Canada Corresponding author: Edward
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Membranous nephropathy role of steroids GUIDELINES
Membranous nephropathy role of steroids Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES There is currently no data to support the use of short-term courses of
More informationBelimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
ARD Online First, published on April 5, 2012 as 10.1136/annrheumdis-2011-200937 1 Unit for Clinical Therapy Research, Infl ammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden 2 Division
More informationEfficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: a nationwide multicentre study
Efficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: a nationwide multicentre study D.-J. Park 1, J.-H. Kang 1, K.-E. Lee 1, S.-C. Bae 2, W.-T.
More informationNephrotic syndrome minimal change disease vs. IgA nephropathy. Hadar Meringer Internal medicine B Sheba
Nephrotic syndrome minimal change disease vs. IgA nephropathy Hadar Meringer Internal medicine B Sheba The Case 29 year old man diagnosed with nephrotic syndrome 2 weeks ago and complaining now about Lt.flank
More informationCorporate Presentation January 2013
NASDAQ: ANTH Corporate Presentation January 2013 1 Forward Looking Statements This presentation contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationRenal Flare as a Predictor of Incident and Progressive CKD in Patients with Lupus Nephritis
Article Renal Flare as a Predictor of Incident and Progressive in Patients with Lupus Nephritis Samir V. Parikh,* Haikady N. Nagaraja, Lee Hebert,* and Brad H. Rovin* Summary Background and objectives
More information29/10. Treatment (brand name, manufacturer): For the treatment of: Background: Rituximab (MabThera, Roche) SLE in adults (unlicensed)
GENERAL POLICY Policy Ref: 29/10 Treatment (brand name, manufacturer): For the treatment of: Background: Commissioning position: Rituximab (MabThera, Roche) SLE in adults (unlicensed) There are frequent
More informationIf It s Not One Thing It s Another: Transformation of Lupus Nephritis
HALLWAY CONSULT If It s Not One Thing It s Another: Transformation of Lupus Nephritis By Julie Barsalou, MD, FRCPC; Rohan John, MD; and Joanne M. Bargman, MD, FRCPC A 25-year-old Haitian-born woman presents
More informationLong-Term Followup of Patients Treated With Total Lymphoid Irradiation for Lupus Nephritis
ARTHRITIS & RHEUMATISM Vol. 46, No. 4, April 2002, pp 1014 1018 DOI 10.1002/art.10216 2002, American College of Rheumatology Long-Term Followup of Patients Treated With Total Lymphoid Irradiation for Lupus
More informationSystemerkrankungen mit Nierenbeteiligung
Systemerkrankungen mit Nierenbeteiligung ÖGN Fuschl 2012 Irmgard Neumann Wilhelminenspital Wien Induktions-Therapie Generalisiert CYC i.v. pulse = CYC oral CYCLOPS, de Groot, Ann Int Med 2009 RIT vs CYC
More informationTacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study
Kidney International, Vol. 68 (25), pp. 813 817 Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study CHI CHIU MOK,KA HANG TONG,CHI HUNG TO, YUI PONG SIU,
More informationAcute and chronic treatments
21st Annual Meeting of the Swiss Stroke Society Lausanne, 11 January 2018 Vasculitis and stroke : Acute and chronic treatments Pr Mathieu ZUBER Service de Neurologie et NeuroVasculaire Groupe Hospitalier
More informationNierenbeteiligung bei Systemerkrankungen
Nierenbeteiligung bei Systemerkrankungen ÖGN 2018 Irmgard Neumann www.vasculi*s.at Avacopan (CCX168) Small molecule, orally administered Highly selecgve C5aR inhibitor Prevented MPO- ANCA mediated GlomerulonephriGs
More informationRheumatology Advance Access published March 7, Induction treatment of ANCA-associated vasculitis with a single dose of rituximab
Original article Rheumatology Advance Access published March 7, 2014 RHEUMATOLOGY 262 doi:10.1093/rheumatology/ket489 Induction treatment of ANCA-associated vasculitis with a single dose of rituximab Tabitha
More informationManaging Acute Medical Problems, Birmingham Vasculitis. David Jayne. University of Cambridge
Managing Acute Medical Problems, Birmingham 2016 Vasculitis David Jayne University of Cambridge Disclosures Astra Zeneca, Aurinia, BIOGEN, Boehringer, Chemocentryx, Genzyme/Sanofi, GSK, Lilly, Medimmune,
More informationONE of the following:
Medical Coverage Policy Belimumab (Benlysta) EFFECTIVE DATE: 01 01 2012 POLICY LAST UPDATED: 11 21 2017 OVERVIEW Belimumab (Benlysta ) is indicated for the treatment of adult patients with active, autoantibody-positive,
More informationRéférence bibliographique. "Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis"
"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis" Dooley, Mary Anne ; Jayne, David ; Ginzler, Ellen M ; Isenberg, David ; Olsen, Nancy J ; Wofsy, David ; Eitner, Frank ; Appel,
More informationComparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial
(2017) 0, 1 10 journals.sagepub.com/home/lup PAPER Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial N Kamanamool 1,2, A Ingsathit
More informationB-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design
REVIEW B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design Venkat Reddy* 1, David Jayne 2, David Close 3 and David Isenberg 1 Abstract
More informationBiomarkers for Kidney Disease
Biomarkers for Kidney Disease Lessons From Modeling Lupus Nephritis Brad H. Rovin MD, FASN Professor of Medicine and Pathology Director, Division of Nephrology 1 DISCLOSURE STATEMENTS Dr. Rovin has the
More informationValue of repeat biopsy in lupus nephritis flares
To cite: Greloni G, Scolnik M, Marin J, et al. Value of repeat biopsy in lupus nephritis flares. Lupus Science & Medicine 2014;1:e000004. doi:10.1136/lupus-2013-000004 Received 18 December 2013 Revised
More informationHIGH ANTI-DSDNA CONTENT IN SLE IMMUNE COMPLEXES IS ASSOCIATED WITH CLINICAL REMISSION FOLLOWING BELIMUMAB TREATMENT
HIGH ANTI-DSDNA CONTENT IN SLE IMMUNE COMPLEXES IS ASSOCIATED WITH CLINICAL REMISSION FOLLOWING BELIMUMAB TREATMENT A. Sohrabian 1, I. Parodis 2, N. Carlströmer-Berthén 1, C. Sjöwall 3, A. Jönsen 4, A.
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 08/19/14 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
RITUXAN (rituximab) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline
More informationYear In Review: VasculitisPers. Disclosures. Learning Objectives. none 4/16/2018. Describe new medications for the treatment of vasculitis
Year In Review: VasculitisPers Cailin Sibley, M.D., M.H.S. Director, Vasculitis Clinic April 27 th, 2018 NTEREST DISCLOSURE Disclosures none Learning Objectives Describe new medications for the treatment
More informationAurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis
August 15, 2016 Aurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis Conference call and webcast at 8am ET First therapeutic agent to meet
More informationRituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future
mini review http://www.kidney-international.org & 2007 International Society of Nephrology Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus:
More informationDevelopment of SLE among Possible SLE Patients Seen in Consultation: Long-Term Follow-Up. Disclosures. Background. Evidence-Based Medicine.
Development of SLE among Patients Seen in Consultation: Long-Term Follow-Up Abstract # 1699 May Al Daabil, MD Bonnie L. Bermas, MD Alexander Fine Hsun Tsao Patricia Ho Joseph F. Merola, MD Peter H. Schur,
More informationENFERMEDADES AUTOINMUNES SISTÉMICAS. Dr. J. María Pego Reigosa
ENFERMEDADES AUTOINMUNES SISTÉMICAS Dr. J. María Pego Reigosa ABSTRACT NUMBER: 888 PHASE 3 TRIAL RESULTS WITH BLISIBIMOD, A SELECTIVE INHIBITOR OF B-CELL ACTIVATING FACTOR, IN SUBJECTS WITH MODERATE-TO-SEVERE
More informationNew Protocols for Treatment of Class IV Lupus Nephritis with Emphasis on Rituximab as the Sole Maintenance Therapy
September 218 KUWAIT MEDICAL JOURNAL 343 Original Article New Protocols for Treatment of Class IV Lupus Nephritis with Emphasis on Rituximab as the Sole Maintenance Therapy Kamel El-Reshaid 1, Wael El-Reshaid
More informationRandom spot urine protein to creatinine ratio is a reliable measure of proteinuria in lupus nephritis in Koreans
Random spot urine protein to creatinine ratio is a reliable measure of proteinuria in lupus nephritis in Koreans I.A. Choi, J.K. Park, E.Y. Lee, Y.W. Song, E.B. Lee Division of Rheumatology, Department
More informationApproach to Glomerular Diseases: Clinical Presentation Nephrotic Syndrome Nephritis
GLOMERULONEPHRITIDES Vivette D Agati Jai Radhakrishnan Approach to Glomerular Diseases: Clinical Presentation Nephrotic Syndrome Nephritis Heavy Proteinuria Renal failure Low serum Albumin Hypertension
More informationResearch Article Clinicopathological Correlation in Asian Patients with Biopsy-Proven Lupus Nephritis
International Nephrology Volume 2015, Article ID 857316, 6 pages http://dx.doi.org/10.1155/2015/857316 Research Article Clinicopathological Correlation in Asian Patients with Biopsy-Proven Lupus Nephritis
More informationCooper et al. Pediatric Rheumatology (2018) 16:65 (Continued on next page)
Cooper et al. Pediatric Rheumatology (2018) 16:65 https://doi.org/10.1186/s12969-018-0279-0 RESEARCH ARTICLE Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment
More informationUse of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome
Pediatr Nephrol (2003) 18:833 837 DOI 10.1007/s00467-003-1175-4 BRIEF REPORT Gina-Marie Barletta William E. Smoyer Timothy E. Bunchman Joseph T. Flynn David B. Kershaw Use of mycophenolate mofetil in steroid-dependent
More informationTell me more about vasculitis. Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital
Tell me more about vasculitis Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital Talk overview Case study ANCA-associated vasculitis What is ANCA vasculitis? What causes ANCA
More informationLupus Nephritis: Maintenance Therapy for Lupus Nephritis Do We Now Have a Plan?
Lupus Nephritis: Maintenance Therapy for Lupus Nephritis Do We Now Have a Plan? Oliver Lenz,* Ahmed A. Waheed, Abdur Baig, Alexander Pop, and Gabriel Contreras* Summary Lupus nephritis (LN) increases the
More informationArthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS
Arthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS Introduction: There is perhaps no rheumatic disease that evokes so much fear and confusion among both patients
More informationC1q nephropathy the Diverse Disease
C1q nephropathy the Diverse Disease Danica Galešić Ljubanović School of Medicine, University of Zagreb Dubrava University Hospital Zagreb, Croatia Definition Dominant or codominant ( 2+), mesangial staining
More informationObservations on the occurrence of exacerbations in clinical course of systemic lupus erythematosus
112 ORIGINAL Observations on the occurrence of exacerbations in clinical course of systemic lupus erythematosus Reiko Tomioka 1, Kenji Tani 2,KeikoSato 1, Chiyuki Suzuka 1, Yuko Toyoda 1, Jun Kishi 1,
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Update on Granulomatosis with Polyangiitis (Wegener s) Learning Objectives Identify the clinical features of granulomatosis with
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/47854 holds various files of this Leiden University dissertation Author: Wilhelmus, S. Title: Systemic lupus erythematosus: pathogenesis, diagnosis, and
More informationSLE and Immunodeficiency. Chng Hiok Hee Department of Rheumatology, Allergy and Immunology Tan Tock Seng Hospital, Singapore
SLE and Immunodeficiency Chng Hiok Hee Department of Rheumatology, Allergy and Immunology Tan Tock Seng Hospital, Singapore Focus on Primary antibody immunodeficiency disorders associated with SLE. Secondary
More informationClinical Commissioning Policy: Rituximab for the treatment of idiopathic membranous nephropathy in adults
Clinical Commissioning Policy: Rituximab for the treatment of idiopathic membranous nephropathy in adults Reference: NHS England: 16047/P NHS England INFORMATION READER BOX Directorate Medical Operations
More informationTHE KIDNEY AND SLE LUPUS NEPHRITIS
THE KIDNEY AND SLE LUPUS NEPHRITIS JACK WATERMAN DO FACOI 2013 NEPHROLOGY SIR RICHARD BRIGHT TERMINOLOGY RENAL INSUFFICIENCY CKD (CHRONIC KIDNEY DISEASE) ESRD (ENDSTAGE RENAL DISEASE) GLOMERULONEPHRITIS
More informationImmunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis
Clinical Kidney Journal, 2017, vol. 10, no. 4, 470 474 doi: 10.1093/ckj/sfx014 Advance Access Publication Date: 12 April 2017 Original Article ORIGINAL ARTICLE Immunoglobulin levels and infection risk
More informationCorrelation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies
Original Article Correlation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies Col K Narayanan *, Col V Marwaha +, Col K Shanmuganandan #, Gp Capt S Shankar
More informationComplement in vasculitis and glomerulonephritis. Andy Rees Clinical Institute of Pathology Medical University of Vienna
Complement in vasculitis and glomerulonephritis Andy Rees Clinical Institute of Pathology Medical University of Vienna 41 st Heidelberg Nephrology Seminar March 2017 The complement system An evolutionary
More informationCase Presentation Turki Al-Hussain, MD
Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory
More informationjournal of medicine The new england Sequential Therapies for Proliferative Lupus Nephritis abstract
The new england journal of medicine established in 8 march 4, 004 vol. 350 no. 0 Sequential Therapies for Proliferative Lupus Nephritis Gabriel Contreras, M.D., M.P.H., Victoriano Pardo, M.D., Baudouin
More informationCase Rep Nephrol Urol 2013;3: DOI: / Published online: January 27, 2013
Published online: January 27, 2013 1664 5510/13/0031 0016$38.00/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license),
More informationKidney disease associated with autoimmune disease
Kidney disease associated with autoimmune disease Masaomi Nangaku Division of Nephrology and Endocrinology the University of Tokyo Graduate School of Medicine, Japan M-type Phospholipase A2 Receptor as
More informationClinical Commissioning Policy: Rituximab For ANCA Vasculitis. December Reference : NHSCB/ A3C/1a
Clinical Commissioning Policy: Rituximab For ANCA Vasculitis December 2012 Reference : NHSCB/ A3C/1a NHS Commissioning Board Clinical Commissioning Policy: Rituximab For The Treatment Of Anti-Neutrophil
More informationjournal of medicine The new england Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis abstract
The new england journal of medicine established in 1812 november 24, 2005 vol. 353 no. 21 Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis Ellen M. Ginzler, M.D., M.P.H., Mary
More informationManagement and Prognosis of Lupus Nephritis
Management and Prognosis of Lupus Nephritis Dimitrios T Boumpas National and Kapodistrian University of Athens Special thanks to G Bertsias, University of Crete Key Questions in Lupus Nephritis Is it common?
More informationMandana Nikpour 1,2, Murray B Urowitz 1*, Dominique Ibanez 1, Paula J Harvey 3 and Dafna D Gladman 1. Abstract
RESEARCH ARTICLE Open Access Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective
More information